☰

Empresas y finanzas

Collexis Holdings Acquires SyynX Solutions, Expands Application Portfolio


    Collexis Holdings, Inc. (OTCBB: CLXS), a leading developer of high
    definition search and discovery software, announced today that it has
    acquired its long-time development partner, SyynX Solutions, a
    privately-held software company based in Cologne, Germany.

    For nearly a decade, Collexis and SyynX have collaborated on both
    a technical and commercial level and the transaction is designed to
    combine the respective strengths of each company. Recently, the two
    organizations partnered to design the next generation in social
    networking, an online platform for the life sciences community. The
    comprehensive system of pre-populated expert profiles, coupled with
    the ability to analyze all associated professional connections within
    the network, allows scientists and researchers across multiple
    organizations to share data and collaborate in ways never before
    considered.

    SyynX software applications, based on the proprietary Collexis
    Fingerprint technology, are already a valuable research tool employed
    globally by organizations such as Johns Hopkins, the Mayo Clinic,
    Harvard University's Dana Farber Cancer Institute and The National
    Institutes of Health.

    "The SyynX software component is an ideal strategic complement to
    our existing capabilities as the market leader in high-definition
    search and discovery solutions," said Bill Kirkland, CEO of Collexis.
    "Our comprehensive offerings address a growing market trend, as
    scientists are increasingly recognizing the essential role that
    informatics, database and workflow solutions play in more effectively
    managing research programs and driving higher productivity. We believe
    that the acquisition of SyynX will position Collexis as a global
    leader in providing these solutions, and our value proposition to
    clients will be stronger as a result."

    SyynX has been providing innovative knowledge solutions and text
    mining applications to solve the unique challenges of the life science
    and healthcare market since 1999, including: Merck Sharp & Dohme; the
    World Health Organization (WHO - Alliance for Health Policy and
    Systems Research); BioSci project (EMBO) and Asklepios Hospital Group,
    the largest privately held healthcare system operating 100 hospitals
    in Germany and six in the United States, where SyynX has implemented a
    comprehensive skills and knowledge management system.

    "After working together with the Collexis team for several years,
    the SyynX team is more than excited about bringing the two companies
    together," said Christian Herzog, MD, CEO of SyynX Solutions. "The
    Collexis Fingerprint core technology, combined with the applications
    built by SyynX, will provide a great advantage to existing customers,
    as well as future ones."

    "This formidable combination will enhance the world of knowledge
    management, text and knowledge mining solutions not limited to the
    life sciences market," said Martin Schmidt, Chief Technology Officer
    of SyynX. "The strong potential of this corporate collaboration is
    perhaps most evident as we prepare to launch our unprecedented social
    networking and collaboration platform for the biomedical research
    community in early 2008. We believe that this platform will change the
    way research is done."

    About Collexis Holdings, Inc.

    Collexis Holdings, Inc., a leading developer of High Definition
    Search and Discovery software since 1999, is headquartered in
    Columbia, South Carolina (USA) with operations in Geldermalsen, The
    Netherlands and, with the acquisition of SyynX, in Cologne, Germany.
    Collexis' proprietary technology builds conceptual profiles of text,
    called Fingerprints, from documents, websites, e-mails and other
    digitized content and matches them with a comprehensive list of
    pre-defined "fingerprinted" concepts to make research results more
    relevant and efficient. This matching of concepts eliminates the
    ambiguity and lack of priority associated with word searches. The
    results are often described as "finding needles in many haystacks."
    Through this novel approach, Collexis can build unique applications to
    search, index and aggregate information as well as prioritize, trend
    and predict data based on sources in multiple industries without the
    limitations of language or dialect. Shares of Collexis common stock
    are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB).
    For more information, please visit www.collexis.com.

    About SyynX Solutions GmbH

    SyynX Solutions GmbH is a German software company focused on text
    mining-based applications for the areas of life science and health
    care. Collexis and SyynX have co-operated closely for nearly a decade
    on the technical and commercial level. The SyynX applications based on
    the Collexis Fingerprint technology are used by customers like
    universities, pharmaceutical and biotech companies around the world.
    For more information, please visit www.syynx.de.

    Some of the statements made in this press release may constitute
    forward-looking statements within the meaning of the Private
    Securities Litigation Reform Act of 1995. These forward-looking
    statements are based on management's current expectations and include
    known and unknown risks, uncertainties and other factors, many of
    which the company is unable to predict or control, that may cause the
    company's actual results or performance to differ materially from any
    future results or performance expressed or implied by such
    forward-looking statements. These statements involve risks and
    uncertainties, including risks and uncertainties associated with the
    acquisition of SyynX, with whether the benefits of the acquisition
    will occur as anticipated, and with the planned launch of the
    company's social networking and collaboration platform for the
    biomedical research community. These risks and uncertainties are in
    addition to other factors detailed from time to time in the company's
    filings with the SEC, including the section entitled "Risk Factors" in
    its transition report on Form 10-KSB for the period ended June 30,
    2007. The company cautions investors that any forward-looking
    statements made by the company are not necessarily indicative of
    future performance. The company is not responsible for updating the
    information contained in this press release beyond the published date,
    or for changes made to this document by wire services or Internet
    services.